HSCA Comments to the Food and Drug Administration on the Reauthorization of the Generic Drug User Fee Amendments (GDUFA)
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to comment on the Food and Drug Administration’s (FDA) proposed recommendations to Congress for Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years 2028–2032 and the recent public meeting addressing these proposals. HSCA supports the FDA’s continued commitment to ensuring a stable and affordable generic drug market and welcomes the opportunity to share our thoughts on how the reauthorization of GDUFA can better serve generics manufacturers, healthcare providers, and patients.
Click here to view the full response.
Lear MoreHealthcare Supply Chain Association Names Michelle Pleiness as New Chair of Board
Washington, D.C. (September 14, 2026) – The Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), today announced that HPS Vice President of Member Development and Customer Relations, Michelle Pleiness, will serve as the new chair of HSCA’s Board of Directors, replacing Capstone Health Alliance President and CEO Tim Bugg. Pleiness has served on the board of HSCA for over 15 years, holding both treasurer and secretary roles.
“Michelle Pleiness is an industry leader in the healthcare supply chain and has long been a valuable member of HSCA’s board of directors. Her experience across different roles on the board and with HPS provides her with a deep understanding of member needs and organizational strategy which will help HSCA and its member GPOs continue to help hospitals, clinics, and other healthcare providers source high-quality products at reasonable prices.” said HSCA President and CEO Angie Boliver. “HSCA is grateful to Tim Bugg for his dedicated leadership as Chair, and we look forward to building on the strong foundation he has helped establish.”
Click here to read more.
Lear MoreHSCA Comments on Senate Finance Committee “Request for Information on Commonsense Policy Options to Lower Drug Prices for Patients”
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide comments in response to the Senate Finance Committee’s request for information (RFI) on policies to lower drug prices for patients. HSCA supports the committee’s continued efforts to enhance affordability for patients and improve access to high-quality medications, and we welcome the opportunity to share our perspective on how a strong, competitive, and resilient supply chain advances those shared goals.
Click here to view the full response.
Lear MoreHSCA Response to the Centers for Medicare & Medicaid Services Request for Information on Pharmacy Benefit Manager Compensation and Data Collection
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading
traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide
comments to the Centers for Medicare and Medicaid Services (CMS) regarding pharmacy benefit manager (PBM) business practices.
Click here to view the full response.
Lear MoreHSCA Applauds House Energy and Commerce Committee and Senate HELP Committee for Advancing Bipartisan Biosimilars Legislation that Will Help Increase Access to Safe Medications
Washington, D.C. (July 29, 2026) – The Healthcare Supply Chain Association (HSCA) and its traditional healthcare group purchasing organization (GPO) members commend the U.S. House Committee on Energy and Commerce for unanimously advancing two bipartisan bills that would expand patient access to lower-cost biosimilars: the Expedited Access to Biosimilars Act (H.R. 9661), led by Reps. Nick Langworthy (R-NY) and Kim Schrier (D-WA), and the Biosimilar Red Tape Elimination Act (H.R. 5526), led by Reps. August Pfluger (R-TX) and Greg Landsman (D-OH). This comes after the Senate Health, Education, Labor, and Pensions (HELP) Committee’s recent advancement of two companion bills, the Expedited Access to Biosimilars Act (S.1414), led by Sen. Rand Paul (R-KY), and the Biosimilars Red Tape Elimination Act (S.1954), led by Sens. Mike Lee (R-UT) and Ben Ray Lujan (D-NM).
“Biosimilars are one of the most effective tools for expanding generic competition in the prescription drug marketplace. Biosimilars have the potential to increase patient access to life-saving medications and reduce costs for the entire healthcare system,” said HSCA President and CEO Angie Boliver. “HSCA has long advocated for policies that ensure a pathway to market for biosimilars that prioritize patient safety while encouraging development and uptake. Eliminating outdated, duplicative testing requirements will help patients get faster access to safe, affordable treatments.”
Click here to view the full statement.
Lear More